Oxford Nanopore Technologies
Oxford Nanopore Technologies develops scalable, real-time DNA/RNA sequencing tools that enable fast, accessible analysis across research, healthcare, and global diagnostics.
About
Oxford Nanopore Technologies, founded in 2005, developed a novel generation of DNA/RNA sequencing technology that delivers rich data, is fast, accessible, and easy to use. The company aims to disrupt conventional biological analysis and enable new applications with a profound, positive impact on society.
Its sequencing technology is used across a wide range of biological research areas—including human genetics, cancer, agriculture, food science, environmental monitoring, and pathogen analysis. Oxford Nanopore’s platform has been deployed in over 70 countries to sequence SARS-CoV-2, the virus responsible for COVID-19.
Nanopore sequencing provides real-time analysis, enabling rapid insights in fully scalable formats—from handheld devices to population-scale systems. It can analyse native DNA or RNA, and sequence any fragment length, from short to ultra-long reads.
Headquartered in Oxford, UK, the company also has offices in Cambridge (UK), New York, Cambridge and San Francisco (US), Singapore, Shanghai, and Beijing, and sells its technology in nearly 100 countries.
